The success of cancer immunotherapies in recent years has shown the power of using the body’s own immune system to fight cancer. However, today’s immunotherapies work in only a subset of patients. We believe it may be possible to expand the promise of immunotherapy to more patients and more cancer types by leveraging the latest scientific discoveries about how immune cells work.
At Palleon we have made great strides in understanding the ways that cells recognize and react to one another based on the distinctive chains of sugar molecules coating their surfaces. Modifying these interactions gives us the opportunity to extend the benefits of immunotherapy, activating a broader spectrum of anti-cancer mechanisms and addressing processes like T cell exhaustion that currently limit the utility of cancer immunotherapies for some patients.
Palleon’s clinical trial information
The company has initiated a Phase 1/2 clinical study of E-602 in patients with advanced cancers. The GLIMMER-01 study (NCT05259696) is now enrolling at sites in the U.S. For more information, visit clinicaltrials.gov
Expanded access statement
Palleon is dedicated to developing new therapies for patients with cancer and inflammatory diseases. At this time, Palleon does not have a program to provide its investigational therapies to patients on an expanded access basis. We encourage you to speak with your physician about options that may be right for you including ongoing clinical trials and approved medicines.